MM-474 Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment

Abstract

Minimal residual disease (MRD) platforms carry prognostic and predictive value in hematologic malignancies. Yet, their role and adoption in the real world remains limited. Evaluate trends in self-reported perceptions and utilization of MRD in routine clinical care of multiple myeloma (MM) patients. U.S.-licensed oncologists and hematologists convened at a live meeting in January 2020 (cohort A) and April 2022 (cohort B) to review clinical updates presented at the 2019 and 2022 ASH annual meetings, respectively. Participant characteristics and demographics were collected via an online survey ahead of the meeting. During the meeting, participants responded to queries about their perceptions and use of MRD assessment in MM. In addition, both cohorts A and B were shown updated data on the role of MRD in routine MM care and were polled about MRD afterwards. Data were summarized using descriptive statistics. Cohort A and B were comprised of 58 and 51 participants, respectively; 60.3% and 60.8% identified their primary specialty as hematology/oncology; 60.4% and 84.3% practiced in a community-based setting. Myeloma was one of the top three hematologic malignancies treated by both cohorts. MRD status was not assessed in patients by 53.8% of cohort A (n=52) compared to 54.0% of participants in cohort B. Lack of evidence was a reported barrier in both cohorts (64.0% and 29.5% in cohorts A and B, respectively); additional lack of necessary guidelines for MRD utilization was a noted barrier in cohort B (30.8%). After reviewing new clinical data on MRD assessment in MM, 71.2% of cohort A participants requested more data and 78.0% of cohort requested guidelines to compel them to use or increase their use of MRD in MM. Over the past two years, community provider perception and utilization of MRD has not changed significantly, although providers demonstrated receptiveness to utilizing MRD if provided with adequate guidelines. It should be noted that current NCCN Guidelines and the International Myeloma Working Group guidelines provide guidance on the role of MRD during response assessment and surveillance periods. These findings suggest that further education on the role of MRD in routine care is needed.